• Neuren’s Phase 2 clinical trial is now open for enrolment
  • Neuroscientific submits an ethics approval request for Phase 1 trial
  • Cannabis play Little Green Pharma signs $2m supply deal

Neurological disorders specialist Neuren Pharmaceuticals (ASX:NEU) announced today that its Phase 2 clinical trial of NNZ-2591 in Angelman syndrome (AS) is open for enrolment.

The first patients are expected to enter the trial imminently at the Children’s Health Queensland Hospital.

The open label Phase 2 trial will enrol a single group of up to 20 children aged 3 to 17 years with AS.

All subjects will receive NNZ-2591 as an oral liquid dose twice daily, with titration up to the target mg/kg dose during the first six weeks of treatment, subject to safety and tolerability.

The treatment period is preceded by four weeks of observation, and a follow-up assessment will be made two weeks after end of treatment.

The overall aim of the Phase 2 trial is to generate information to inform the design of a subsequent registration trial, with top-line results anticipated in H1 2023.

There are currently no approved medicines for AS, which is characterised by severe developmental delay and learning disabilities that become noticeable by the age of 6–12 months.

Meanwhile, Neuroscientific Biopharma (ASX:NSB) has submitted an application for Human Research Ethics Committee (HREC) approval to commence a Phase 1 clinical trial of lead drug candidate EmtinB.

EmtinB is being studied as a treatment for multiple sclerosis and Alzheimer’s disease.

The Phase 1 clinical trial is expected to enrol up to 88 healthy adult volunteers, with the endpoint being the safety and tolerability of EmtinB versus placebo.


Neuren and NSB prices today:



Other notable ASX healthcare announcements today

Little Green Pharma (ASX:LGP) has signed a two-year ~$2 million medicinal cannabis supply agreement with Ilios Santé in Germany.

Ilios Santé will purchase minimum annual quantities of a high-THC white-label medicinal cannabis flower product being developed by LGP.

LGP says the deal represents a validation of its key strategy of developing bespoke, high-value white label strains for export to lucrative jurisdictions like Europe.

Imaging devices company IMEXHS (ASX:IME) has entered into a new and expanded three-year contract with major hospital group, Colsubsidio, in Colombia.

The deal allows IMEXHS to operate Colsubsidio’s entire radiology service across the hospital’s network, increasing the number of sites covered from 23 to 28.

The new contract including price and volume increases is expected to increase IME’s annual recurring revenue by up to 20% from the $6m currently.


Little Green Pharma and IMEXHS share prices